BBOT
HealthcareBridgeBio Oncology Therapeutics, Inc.
$11.34
$-0.95 (-7.73%)
Jan 5, 2026
Price History (1Y)
Analysis
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a biotechnology company in the healthcare sector with 81 employees. Its market capitalization stands at $907.07 million. The financial health of BridgeBio Oncology Therapeutics, Inc. is marked by significant net income and EBITDA losses, totaling -$114,934,000 and -$124,042,000 respectively over a trailing twelve-month period. The company has minimal debt, with a debt-to-equity ratio of 0.65, but its cash position is substantial at $468.28 million. The valuation context for BridgeBio Oncology Therapeutics, Inc. includes an unfavorable price-to-earnings ratio of -5.20 and an enterprise value-to-EBITDA ratio of -4.17. The company has a price-to-book ratio of 2.01 but lacks data on other key metrics such as revenue growth rates or dividend yields.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide 3-kinase malignancies. The company's product pipeline includes BBO-8520, a direct inhibitor targeting the on and off states of KRAS that is in Phase I clinical trial to treat patients with KRASG12C mutant non-small cell lung cancer; and BBO-10203, an orally bioavailable small molecule that is in Phase I clinical trial for treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS pancreatic ductal adenocarcinoma (PDAC), KRAS mutant colorectal cancer (CRC), and KRAS mutant NSCLC. It is also developing BBO-11818, an orally bioavailable pan KRAS on/off inhibitor that is in Phase I clinical trial to treat patients with KRASG12D and KRASG12V mutant NSCLC, PDAC, and CRC. The company was founded in 2016 is headquartered in South San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $907.07M
- P/E Ratio
- N/A
- 52-Week High
- $14.87
- 52-Week Low
- $8.50
- Avg Volume
- 171.43K
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 81